Articles

Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study
Patients with multiple sclerosis (MS) and healthy controls were asked about sleep, fatigue, sleepiness, and depression and had a polysomnographic study. Central hypersomnias were frequent in patients with MS who had fatigue and sleepiness during the day. These results warrant careful attention to these symptoms in patients with MS.

Page 20

Association of Migraine With Incident Hypertension After Menopause: A Longitudinal Cohort Study
Migraine prevalence decreases after menopause, and migraine has been associated with hypertension. In this longitudinal cohort study, menopausal women with migraine were found to be at an increased risk of hypertension, suggesting that women with migraine could benefit from closer monitoring of their blood pressure.

Page 21

Primary Progressive Aphasia Associated With GRN Mutations: New Insights Into the Nonamyloid Logopenic Variant
Primary progressive aphasia (PPA) is a rare neurodegenerative disorder, and in some patients, it may be associated with mutations of the progranulin (GRN) gene. This study characterized the linguistic and cognitive profile and the pattern of gray matter atrophy in 32 patients with PPA associated with GRN mutations. The results suggest that GRN testing may be warranted in patients with the logopenic variant of PPA, whether familial or sporadic.

Page 26

Continued
Clinical/Scientific Notes

SARS-CoV-2 Encephalitis Presenting as a Clinical Cerebellar Syndrome: A Case Report

There is an expanding spectrum of neurologic conditions associated with coronavirus disease 2019 (COVID-19). In this case report, the authors describe a patient with encephalitis presenting with pancerebellar signs and in whom severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA was detected in the CSF. This report suggests that SARS-CoV-2 may directly contribute to neural dysfunction in some patients with COVID-19.

Page 27

NEW EPISODE

July 6, 2021

Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis (see p. 24)

In the first segment, Dr. Jeff Burns talks to neurologist Dr. Daniel Gibbs about his Alzheimer disease diagnosis and experience participating in a clinical trial for aducanumab. In the second part of the podcast, Dr. Gregg Day speaks with Dr. Josep Dalmau about NMDAR antibodies in patients with first episode psychosis and the utility of criteria for autoimmune psychosis.

Disclosures can be found at Neurology.org.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by completing the online podcast quiz.